{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:38:54Z","timestamp":1773693534111,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thekneejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Knee"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.knee.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:46:01Z","timestamp":1751701561000},"page":"407-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-4324","authenticated-orcid":false,"given":"Thomas R W","family":"Ward","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert U","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C","family":"Eastley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.knee.2025.06.006_b0005","article-title":"Management of tenosynovial giant cell tumor: a neoplastic and inflammatory disease","volume":"4","author":"Healey","year":"2020","journal-title":"J Am Acad Orthop Surg Glob Res Rev"},{"issue":"10","key":"10.1016\/j.knee.2025.06.006_b0010","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. a registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.knee.2025.06.006_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260795","article-title":"Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-a systematic review and meta-analysis","volume":"16","author":"Siegel","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.knee.2025.06.006_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-016-0060-4","article-title":"UK guidelines for the management of soft tissue sarcomas","volume":"6","author":"Dangoor","year":"2016","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.knee.2025.06.006_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.knee.2025.06.006_b0030","first-page":"356","article-title":"Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled","volume":"107","author":"Barile","year":"2004","journal-title":"Radiol Med"},{"key":"10.1016\/j.knee.2025.06.006_b0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/2156-7514.152343","article-title":"Malignant tenosynovial giant cell tumor of the leg: a radiologic-pathologic correlation and review of the literature","volume":"5","author":"Richman","year":"2015","journal-title":"J Clin Imaging Sci"},{"issue":"1","key":"10.1016\/j.knee.2025.06.006_b0040","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1186\/s12885-018-5188-6","article-title":"Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy","volume":"18","author":"Nakayama","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.knee.2025.06.006_b0045","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CAD.0000000000000844","article-title":"Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour","volume":"31","author":"Rebuzzi","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.knee.2025.06.006_b0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ejso.2021.11.123","article-title":"Incidence of unplanned excisions of soft tissue sarcomas in the Netherlands: a population-based study","volume":"48","author":"Melis","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.knee.2025.06.006_b0055","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.suc.2022.04.002","article-title":"The Implications of an Unplanned Sarcoma Excision (the \u201cWhoops\u201d operation)","volume":"102","author":"Grignol","year":"2022","journal-title":"Surg Clin North Am"},{"issue":"4","key":"10.1016\/j.knee.2025.06.006_b0060","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.knee.2017.03.011","article-title":"Pigmented villonodular synovitis of the knee: a retrospective analysis of 214 cases at a UK tertiary referral centre","volume":"24","author":"Patel","year":"2017","journal-title":"Knee"},{"issue":"3","key":"10.1016\/j.knee.2025.06.006_b0065","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030941","article-title":"One-stage synovectomies result in improved short-term outcomes compared to two-stage synovectomies of diffuse-type tenosynovial giant cell tumor (D-TGCT) of the knee: a multicenter, retrospective, cohort study","volume":"15","author":"Spierenburg","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.knee.2025.06.006_b0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12306-023-00793-y","article-title":"Total knee arthroplasty in pigmented villonodular synovitis osteoarthritis: a systematic review of literature","volume":"108","author":"Panciera","year":"2024","journal-title":"Musculoskelet Surg"},{"issue":"10","key":"10.1016\/j.knee.2025.06.006_b0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/fon-2023-0238","article-title":"The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor","volume":"20","author":"Tap","year":"2024","journal-title":"Future Oncol"},{"issue":"10445","key":"10.1016\/j.knee.2025.06.006_b0080","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"issue":"10197","key":"10.1016\/j.knee.2025.06.006_b0085","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.knee.2025.06.006_b0090","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.knee.2025.06.006_b0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg Oncol"}],"container-title":["The Knee"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968016025001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968016025001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:26:52Z","timestamp":1761395212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968016025001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":19,"alternative-id":["S0968016025001619"],"URL":"https:\/\/doi.org\/10.1016\/j.knee.2025.06.006","relation":{},"ISSN":["0968-0160"],"issn-type":[{"value":"0968-0160","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current management of Tenosynovial Giant Cell Tumours of the knee in the United Kingdom","name":"articletitle","label":"Article Title"},{"value":"The Knee","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.knee.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}